Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PAXIPAM (halazepam) is an oral benzodiazepine tablet approved in 1981 by Merck & Co. for anxiety disorders. It functions as a central nervous system depressant with anxiolytic properties, though specific mechanism of action data is not available in this profile.
Moderate competitive pressure (30/100) indicates a stable but threatened market position; expect smaller teams focused on retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PAXIPAM presents limited growth opportunities given its LOE-approaching lifecycle and zero linked job postings; roles focus on defending market share and managing generic transition. Career advancement depends on portfolio rotation or moving into lifecycle management expertise.
Worked on PAXIPAM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.